PuSH - Publikationsserver des Helmholtz Zentrums München

Immunoprophylaxis against HTLV-III/LAV-infection


AIDS-Forschung 1, 117-123 (1986)
Verlagsversion bestellen
The discovery and isolation of the virus responsible for AIDS, HTLV-III/LAV, has opened up the possibility of developing a vaccine against the disease. Production of a live vaccine with HTLV-III/LAV does not appear to be feasible, either at present nor in the near future. An alternative possibility is the development of a live vaccine using Vaccinia recombinant viruses containing HTLV-III/LAV envelope genes. At present, however, the approach with the greatest prospect of success is the development of a vaccine based on virus envelope proteins produced with the aid of expression vectors. Further alternatives on which the production of vaccines might be based in the future are synthetic peptides or anti-idiotype antibodies. A prerequisite for the development and application of HTLV-III/LAV immunisation is that the virus is shown to have a limited variability. Use of all available strategies of vaccine production, as well as reliable animal model systems, remain important for the successful establishment of an immunoprophylactic program against HTLV-III/LAV infection.
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
ISSN (print) / ISBN 0179-3098
Quellenangaben Band: 1, Heft: 3, Seiten: 117-123 Artikelnummer: , Supplement: ,
Verlag Schulz
Begutachtungsstatus Peer reviewed